Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARETHA: Verquvo in Heart Failure Patients with CardioMEMS HF System
2024-514111-10-00Phase 4Completed
- Sponsor
- Rigshospitalet
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF) comparing Verquvo with Placebo (2 arms). Primary endpoint: Change in diastolic pulmonary artery pressure. Started Sep 2024; status: completed.
02
Drugs
vericiguat
03
Conditions
heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on 2024-514111-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514111-10-00.